• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

INBU rumors

Anonymous

Guest
...are starting. Upper management please understand that no matter how solid of a rep you are, this is extremely challenging for us to work through. The sooner the better so those of us that are lucky enough to stay can get re-motivated and start selling again at the levels we were used to. Good luck to all.
 








Not the original poster but people we are hearing about territory sizes, geographies changing - not all white territories "remaining the same" as originally stated. But my take is it's typical speculation no one really knows. Two weeks can't come quick enough to end this misery.